article thumbnail

Food Insecurity is a Leading Health-Related Social Need Among Patients With Diabetes

Pharmacy Times

Screening tools are becoming widely used to help clinicians address the needs of patients with diabetes to improve health outcomes.

Food 52
article thumbnail

Do patients care about accelerated approval drugs?

World of DTC Marketing

Do patients care? The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Do patients care? If you’re a cancer patient and your oncologist is prescribing a drug approved via accelerated Approval, are you going to refuse treatment? The answer to that would be “no.”

Patients 200
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Can ROI ever be used with patient-centric?

World of DTC Marketing

Patient-centric has become buzzwords within the industry. It should be patient-centric if there an ROI. There are many different types of cancer and how they destroy the body differs by patient populations. It’s just too damn easy to take a pill rather than give up bad foods or exercise.

Patients 201
article thumbnail

Half of cancer deaths are preventable

World of DTC Marketing

Globally, nearly half of deaths due to cancer can be attributable to preventable risk factors, including three leading risks of smoking, drinking too much alcohol, or having a high body mass index, a new paper suggests. The costs associated with direct cancer care are staggering for patients and their families. health care spending.

Food 229
article thumbnail

Stalicla signs licence deal for Evgen Pharma’s lead asset SFX-01

Pharmaceutical Technology

Swiss biotech company Stalicla has signed a licensing deal with Evgen Pharma for the latter’s lead asset, SFX-01, in neurodevelopmental disorders and schizophrenia. in milestone payments that include $5m upon receipt of the investigational new drug (IND) from the US Food and Drug Administration (FDA), which is expected late next year.

Leads 59
article thumbnail

Pharming undertakes Joenja’s first shipments to APDS patients in US

Pharmaceutical Technology

Pharming Group has conducted the first commercial shipments of oral selective PI3Kδ inhibitor Joenja (leniolisib) to patients diagnosed with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the US. In March 2023, Joenja secured approval from the US Food and Drug Administration (FDA) to treat the targeted patients.

article thumbnail

4DMT’s CF gene therapy posts early cues for improving patient outcomes

Pharmaceutical Technology

The use of 4D Molecular Therapeutics’ (4DMT) aerosolised gene therapy 4D-710 has improved the quality-of-life and spirometry-measured outcomes in three cystic fibrosis patients , based on early results from a Phase I/II study presented at this year’s annual meeting of the European Cystic Fibrosis Society (ECFS).